Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

GreenBank Engages Medical Marijuana Consultant

C.GBC, BIOGY

Toronto, Ontario--(Newsfile Corp. - April 22, 2014) - GreenBank Capital Inc (CNSX: GBC) ("GreenBank") announces that it has engaged Dr Stefan A Hulea as medical marijuana consultant. Dr Hulea will provide medical marijuana consulting services with respect to the most appropriate marijuana plants and primary growing processes to be utilized in order to maximize the profit potential inherent in the proposed growing operations of GreenBank's subsidiary Canada Marijuana Agricorp.

Dr. Hulea is currently authoring a book that highlights the pain alleviation properties of medical marijuana as well as health matters directed at the general public. He has an extensive background in biochemistry and worked for over 25 years in basic and applied biomedical research. He graduated from the University of Bucharest, Romania with a B.Sc.(Hon) in Biochemistry and completed his graduate work in the Department of Biochemistry, King's College London, England, where he earned a Ph.D. in Biochemistry.

Dr. Hulea has published dozens of research papers on a variety of topics including medical marijuana as well as microbial nucleic acids metabolism, the role of complex carbohydrate-binding proteins (lectins) as mediators of host-pathogen interactions, oxidative stress and antioxidant mechanisms in plant and animal cells. In the field of applied research Dr. Hulea took part in the development of a plant extract that was used with very good results in the treatment of severe skin burns as well as some skin disorders. Dr. Hulea was previously a visiting scholar at the University of Illinois at Urbana-Champaign where he conducted research on the molecular mechanisms in cardiovascular disease.

Pursuant to his medical marijuana consulting services, Dr Hulea has been granted a common share purchase warrant entitling the holder to acquire 100,000 common shares at an exercise price of $0.125 per share for 24 months, provided however that in the event that the common shares trade on the CSE at a closing price of greater than $0.50 per share for a period of 5 consecutive trading days the Company may, in its sole discretion, accelerate the expiration date of the warrants.

"Dr Hulea has a distinguished career and his expertise will provide us with unique guidance as our medical marijuana plans evolve," said Danny Wettreich, CEO of GreenBank

About GreenBank

GreenBank is a corporate finance investment business investing in Canadian small cap companies. GreenBank's subsidiary Canada Marijuana Agricorp intends to be a commercial producer of medical marijuana, and GreenBank's subsidiary Bitcoin Angel Capital is seeking to make investments in early stage Bitcoin and other cryptocurrency companies. For more information please see www.GreenBankCapitalinc.com or contact Danny Wettreich at (647) 931 9768 or dw@GreenBankCapitalinc.com.

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of GreenBank Capital Inc. The forward-looking information is based on certain key expectations and assumptions made by the company's management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the company can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and the company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CNSX has not reviewed, approved or disapproved the content of this press release

This news release is not for distribution or dissemination in the United States of America



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today